Comparative Pharmacology
Head-to-head clinical analysis: CEFOTAXIME AND DEXTROSE 2 4 IN PLASTIC CONTAINER versus CEFTRIAXONE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTAXIME AND DEXTROSE 2 4 IN PLASTIC CONTAINER versus CEFTRIAXONE IN PLASTIC CONTAINER.
CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER vs CEFTRIAXONE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefotaxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis.
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis mediated by autolytic enzymes. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
1-2 g IV every 6-8 hours; maximum 12 g/day.
1-2 g intravenously or intramuscularly every 12-24 hours, maximum 4 g daily.
None Documented
None Documented
0.8-1.4 hours (normal renal function); ~2-6 hours in renal impairment; prolonged in neonates and elderly
5.8-8.7 hours in adults; prolonged in neonates (18-25 h), elderly, and renal impairment.
Renal: 50-60% unchanged; biliary: 20-30%; fecal: <5%
Renal (33-67% as unchanged drug), biliary/fecal (24-44% as active drug and metabolites).
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic